Several oral abstracts presented at the American Society of Clinical Oncology’s annual meeting highlight ongoing research of Keytruda, Opdivo, Tecentriq and more in skin cancer.

A combination regimen based on Pfizer's BRAF inhibitor Braftovi achieved a 51% reduction in the risk of death in patients ...

From today many with stage 3B to stage 4 melanoma will now have wider access to Keytruda and the branded drug Tafinlar and Mekinist. Melanoma New Zealand Chief executive Andrea Newland says this ...

IND cleared for pan-RAS molecular glue ERAS-0015 and IND submitted for pan-KRAS inhibitor ERAS-4001, both ahead of schedule; Phase 1 monotherapy data for both programs expected in 2026 Meaningful ...

Cancer specialists and patients have welcomed news that three potentially life-saving skin cancer medicines are to be funded.

When launched, Hikma will have 180 days of U.S. generic market sales exclusivity for this product, which is the generic of Mekinist. “Hikma’s generics business is accelerating its efforts to ...

It is the generic version of Mekinist, a branded product developed by Novartis Pharma AG (NYSE:NVS). As part of the deal, Hikma also entered into a commercial agreement with Novugen under which it ...

Tafinlar and Mekinist combination therapy shows efficacy in glioma treatment for both pediatric and adult patients, with higher response rates in pediatric cases. Objective response rates were 53% for ...

Mekinist (trametinib) is a prescription drug that’s used to treat certain types of cancers and tumors. Mekinist comes as a powder that a pharmacist mixes into an oral solution and an oral tablet.

Mekinist (trametinib) is a prescription drug that treats specific cancers, including skin, lung, thyroid, and brain. Mekinist’s cost may depend on your dosage, whether you have health insurance ...

Eight-year follow-up showed that Tafinlar plus Mekinist continued to improve outcomes for patients with stage 3 melanoma. Tafinlar (dabrafenib) plus Mekinist (trametinib) continued to be efficacious ...

Dublin, Jan. 02, 2024 (GLOBE NEWSWIRE) -- The "TAFINLAR + MEKINIST Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. The report delves deep into the ...